A randomized trial that switched some frail atrial fibrillation patients from vitamin K antagonists (VKAs) to non-vitamin K oral anticoagulants found that such patients had more bleeding and no decrease in thromboembolic events compared to those who stayed on a VKA.
6 Sep 2023
Also, a sterilizer for 3D-printed medical devices, a drug for postpartum depression, and an RSV vaccine for pregnant patients were approved, among other recent FDA actions.
30 Aug 2023
The recommendations on prevention and management of arterial thrombosis and thromboembolism are not a major departure from prepandemic ones, according to an expert panel from the American College of Chest Physicians.
5 Jul 2023
Mortality and time to improvement didn't differ with twice the standard dose of heparin versus a standard or therapeutic dose, but there was a lower rate of new thromboembolic events with no increase in major bleeding, a French trial found.
29 Mar 2023
Acute manifestations of atrial fibrillation warrant clinical attention during hospitalization, at transitions of care, and over the long term, said the American Heart Association (AHA) statement, which reviewed triggers and treatments for the condition.
22 Mar 2023
A patient with end-stage renal disease presented with one week of facial and left-arm edema.
15 Mar 2023
All-cause mortality at 90 days was similar in hospitalized patients randomized to aspirin versus low-molecular-weight heparin (LMWH), and rates of deep venous thrombosis and pulmonary embolism were also low in both groups.
25 Jan 2023
A meta-analysis compared the direct oral anticoagulants (DOACs) apixaban, edoxaban, and rivaroxaban to low-molecular-weight heparin (LMWH) and found that apixaban was usually the most cost-effective option, but that finding hinged on the specific drug price.
4 Jan 2023
We collected the top five most read ACP Hospitalist articles of 2022 and identified some themes.
28 Dec 2022
Potentially beneficial complementary and alternative medicine (CAM) therapies included omega-3 polyunsaturated fatty acids, coenzyme Q10, D-ribose, and L-carnitine, the American Heart Association (AHA) said.
14 Dec 2022